Mr. Dey co-founded Bluejay Diagnostics in 2015, after co-founding Lana Management & Business Research International (LMBRI) in 2007. LMBRI is a management consulting company focused on the launch and marketing of medical products in the US, Japan and EU.
Mr. Dey spent about eight years at LMBRI, consulting with companies such as Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), and Fuji Chemicals. Prior to this, he held executive positions at several firms. From 2005–07, he was Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca). From 2001–05, he was Head of Business Development, Western US, at IMPATH, Inc. Here, he handled three business units and the introduction of a new product, Her2neu Diagnostics, for the treatment of breast cancer, with Herceptin. He was also Chief Business Officer at Genmethrax, Inc; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis).
Mr. Dey is a Bachelor of Science and has a master’s degree in Biochemistry from Visva-Bharati University in India and PhD in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also holds a Master of Business Administration degree (Fulbright Scholarship) from the University of Cambridge.
Mr. Dey co-founded Bluejay Diagnostics in 2015, after co-founding Lana Management & Business Research International (LMBRI) in 2007. LMBRI is a management consulting company focused on the launch and marketing of medical products in the US, Japan and EU.
Mr. Dey spent about eight years at LMBRI, consulting with companies such as Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), and Fuji Chemicals. Prior to this, he held executive positions at several firms. From 2005–07, he was Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca). From 2001–05, he was Head of Business Development, Western US, at IMPATH, Inc. Here, he handled three business units and the introduction of a new product, Her2neu Diagnostics, for the treatment of breast cancer, with Herceptin. He was also Chief Business Officer at Genmethrax, Inc; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis).
Mr. Dey is a Bachelor of Science and has a master’s degree in Biochemistry from Visva-Bharati University in India and PhD in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also holds a Master of Business Administration degree (Fulbright Scholarship) from the University of Cambridge.
Dr. Cook joined Bluejay in 2021. From 2014–21, he served as Chief Executive Officer at NanoHybrids, Inc., a nanotechnology company focused on developing theranostic nanoparticle platform technologies. Here, he was Director and Chairman of the Board from 2020–21, and Senior Scientist from 2014–17, overseeing the development of several core technologies.
Dr. Cook did his PhD in Biomedical Engineering from The University of Texas at Austin, focusing on the design and development of medical diagnostic systems. His postdoctoral work included improving the bioconjugation strategies of nanoparticles for molecular targeting. Dr. Cook also serves as Ad-hoc Reviewer for numerous panels at the National Institute of Health and peer-reviewed scientific journals.
Mr. Gemignani has served on Bluejay’s Board of Directors since November 2021. Mr. Gemignani has served as EVP, Chief Financial Officer of Acacia Pharma Group plc, a hospital pharmaceutical company since January 2020. Prior to Acacia Pharma, Mr. Gemignani served as CFO of Synergy Pharmaceuticals Inc. from 2017 to 2019 where he successfully led the sale of this Nasdaq-listed company’s assets to Bausch Health.
Previously, Mr. Gemignani served as CEO and CFO of Biodel Inc., overseeing business and strategic planning, operations and financing activities of the company. Prior to this, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including, Prudential Financial, Gentium, Novartis and Wyeth. Mr. Gemignani started his career at Arthur Andersen & Co.
Ms. Dey has been a member of Bluejay’s Board of Directors since 2015. She co-founded Bluejay Diagnostics in 2015 and LMBRI, a management consulting company focused on the launch and marketing of medical products in the US, Japan and India, in 2008. Ms. Dey served as LMBRI’s President and CEO since 2008 and is a Board member of Laminar Pharma, Inc. Prior to LMBRI, she spent more than 15 years in healthcare consulting. In these roles, she oversaw healthcare and life sciences product development, sales and marketing, and general management for more than 12 years. Ms. Dey holds a Master’s degree in Mathematics from the State University of Mari El Republic, Russia.